← Back to Search

Other

ACP-044 Dose A for Osteoarthritis Pain

Phase 2
Waitlist Available
Research Sponsored by ACADIA Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights

Study Summary

This trial will compare the effectiveness of ACP-044 to a placebo in treating pain associated with osteoarthritis of the knee.

Eligible Conditions
  • Osteoarthritis Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline to Week 4 in the weekly average of the daily average Numeric Rating Scale (NRS) pain intensity scores.
Secondary outcome measures
Change from Baseline to Week 4 in 12-item Short Form Survey (SF-12).
Change from Baseline to Week 4 in Brief Pain Inventory-Short Form (BPI-sf).
Change from Baseline to Week 4 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score and individual subscale scores for pain, stiffness, and physical function.
+3 more

Side effects data

From 2022 Phase 2 trial • 239 Patients • NCT04855240
19%
Nausea
12%
Headache
9%
Dizziness
6%
Vomiting
2%
Constipation
1%
COVID-19 pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Drug - ACP-044 400 mg Q6H
Drug - ACP-044 1600 mg QD

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug - ACP-044 Dose BExperimental Treatment1 Intervention
ACP-044 Dose B
Group II: Drug - ACP-044 Dose AExperimental Treatment1 Intervention
ACP-044 Dose A
Group III: PlaceboPlacebo Group1 Intervention
Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ACP-044 Dose B
2021
Completed Phase 2
~240
ACP-044 Dose A
2021
Completed Phase 2
~240

Find a Location

Who is running the clinical trial?

ACADIA Pharmaceuticals Inc.Lead Sponsor
46 Previous Clinical Trials
10,879 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Missouri
Arizona
Tennessee
How old are they?
65+
18 - 65
What site did they apply to?
Healthcare Research Network, Inc.
Drug Studies America
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee
2021. "Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05008835.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top